TsGRM Genetiko PAO

TsGRM Genetiko PAO EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of TsGRM Genetiko PAO (GECO.ME) as of Nov 1, 2026 is -74.07. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -29.28 — a change of 152.97% (lower).

EV/FCF

-74.07

YoY

152.97%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of TsGRM Genetiko PAO is 2024 -74.07 . EV/FCF (Enterprise Value to Free Cash Flow) of TsGRM Genetiko PAO was 2023 -29.28 . It decreases by 152.97% lower compared to the previous year.

The TsGRM Genetiko PAO EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2022
-83.66 RUB
Jan 1, 2023
-29.28 RUB
Jan 1, 2024
-74.07 RUB
The TsGRM Genetiko PAO EV/FCF history
YEAREV/FCFYoY
-74.07+152.97%
-29.28-65.00%
-83.66—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TsGRM Genetiko PAO Stock analysis

What does TsGRM Genetiko PAO do? TsGRM Genetiko PAO generates revenue through medical genetic services provided to doctors and patients via its four specialized laboratories. The company offers complex genetic diagnostics for hereditary diseases and reproductive disorders through its Next-Generation Sequencing (NGS) laboratory, Non-Invasive Prenatal Testing (NIPT) laboratory, Oncogenetics laboratory, and Genotyping laboratory. These services are delivered to healthcare professionals and individuals seeking genetic analysis. The firm's laboratory and production complexes form the core of its service delivery model, focusing on diagnostic solutions for medical genetics. TsGRM Genetiko PAO's primary customers are doctors who order genetic tests for their patients and patients directly seeking genetic diagnostics. The company's services include hereditary disease diagnostics and reproductive disorder assessments, which are conducted in its dedicated laboratory facilities. The firm's business model centers on providing specialized genetic testing services through its internal laboratory infrastructure without external partnerships or additional product lines. The company operates exclusively within the medical genetic services sector, delivering diagnostic solutions through its four laboratory divisions. Revenue is derived from the execution of genetic tests across all laboratory types, with no mention of additional product lines or external collaborations. The firm's structure is defined by its internal laboratory network, which serves both medical professionals and end patients. TsGRM Genetiko PAO is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TsGRM Genetiko PAO stock

EV/FCF (Enterprise Value to Free Cash Flow) of TsGRM Genetiko PAO is -74.07 in 2024.

EV/FCF (Enterprise Value to Free Cash Flow) of TsGRM Genetiko PAO changed from -29.28 to -74.07, representing a 152.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) TsGRM Genetiko PAO since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s TsGRM Genetiko PAO with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — TsGRM Genetiko PAO

All Key Metrics — TsGRM Genetiko PAO